Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Lonardo, Enza ^a   Cioffi, Michele ^a   Sancho, Patricia ^a   Sanchez Ripoll, Yolanda ^a   Trabulo, Sara Maria ^a   Dorado, Jorge ^a   Balic, Anamaria ^a   Hidalgo, Manuel ^a   Heeschen, Christopher ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GEMCITABINE; HERMES ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; STAGE SPECIFIC EMBRYO ANTIGEN 1;

ACHILLES HEEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CANCER TISSUE; CELL CLONE; CELL CYCLE ARREST; CELL POPULATION; CELL RENEWAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENERGY; FEMALE; GENE EXPRESSION; HEEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LETHAL ENERGY; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RISK REDUCTION; TUMOR XENOGRAFT;

BIOLOGICAL MARKERS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METFORMIN; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; STROMAL CELLS;

EID: 84885742331     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076518     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Lowenfels AB, Maisonneuve P, (2006) Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20: 197-209.
3. Li D, (2012) Diabetes and pancreatic cancer. Mol Carcinog 51: 64-74.
4. White E, (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12: 401-410.
5. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD, (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.
6. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D, (2012) Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer. Clin Cancer Res.
7. Michaud DS, (2004) Epidemiology of pancreatic cancer. Minerva Chir 59: 99-111.
8. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646.
9. Meric-Bernstam F, Gonzalez-Angulo AM, (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287.
10. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, et al. (2009) Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137: 1102-1113.
11. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, et al. (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40: 685-693.
12. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA, (2010) Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9: 1057-1064.
13. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E, (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69: 6539-6545.
14. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, et al. (2011) Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 5: 355-364.
15. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
16. Jones D, Wagers A, (2008) No place like home: anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol 9: 11-21.
17. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, et al. (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652-4661.
18. Lonardo E, Hermann PC, Mueller M-T, Huber S, Balic A, et al. (2011) Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell.
19. Ouslimani N, Peynet J, Bonnefont-Rousselot D, Therond P, Legrand A, et al. (2005) Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 54: 829-834.
20. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
21. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
22. Lonardo E, Frias-Aldeguer J, Hermann PC, Heeschen C, (2012) Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 11: 1282-1290.
23. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, et al. (2010) Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer 103: 649-655.
24. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, et al. (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822-3829.
25. Rehman J, (2010) Empowering self-renewal and differentiation: the role of mitochondria in stem cells. J Mol Med (Berl) 88: 981-986.
26. Owen MR, Doran E, Halestrap AP, (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348 Pt 3: 607-614.
27. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K, (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511.
28. Hidalgo M, (2010) Pancreatic cancer. N Engl J Med 362: 1605-1617.
29. Hamada S, Masamune A, Takikawa T, Suzuki N, Kikuta K, et al. (2012) Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Biochem Biophys Res Commun 421: 349-354.
30. Jimeno A, Feldmann G, Suarez-Gauthier A, Rasheed Z, Solomon A, et al. (2009) A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 8: 310-314.
31. Gallmeier E, Hermann PC, Mueller MT, Machado JG, Ziesch A, et al. (2011) Inhibition of ATR Function Abrogates the in Vitro and in Vivo Tumorigenicity of Human Colon Cancer Cells Through Depletion of the CD133+ Tumor-Initiating Cell Fraction. Stem Cells 29: 418-429.
32. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, et al. (2011) Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 9: 433-446.